Focalin

A number of new drugs and diagnostic tools recently have been approved, or are on the horizon, to treat attention deficit/ hyperactivity disorder.

Adderall XR: This once-a-day version of Adderall was approved last year by the U.S. Food and Drug Administration.

Ampakine: Now under development by Cortex Pharmaceuticals Inc. as a treatment for Alzheimer's disease, a recent study found this drug might also alleviate some ADHD symptoms.

Atomoxetine: Eli Lilly is seeking federal approval for this nonstimulant treatment for ADHD.

Focalin: Approved last year, this new form of Ritalin reportedly can be given in small doses and lasts longer.

GW320659: Glaxo Wellcome Inc. announced more than a year ago that this drug was in development. Unlike most ADHD medications, it is not a stimulant.

MethyPatch: Noven Pharmaceuticals Inc. is developing a once-a-day patch that would deliver methylphenidate, the same drug used in products such as Ritalin.

OPTAx: The Optical Tracking and Attention Test is a relatively new diagnostic tool that measures how well a child can sit still and pay attention. While not the final word on whether a child has ADHD, it can help doctors determine if the problem exists and measure the success of medication, said Dr. Michael Feld, a psychiatrist who uses the system at Alexian Brothers Behavioral Health Hospital in Hoffman Estates.

Ritalin LA: This once-a-day formulation of Ritalin is awaiting final approval by the FDA.

Copyright The Chicago Sun-Times, Inc.
Provided by ProQuest Information and Learning Company. All rights Reserved.